Bellevue Asset Management’s Structure Therapeutics GPCR Stock Holding History

Bellevue Asset Management’s Portfolio GPCR Stock Details GPCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-15	Closed	-$1.04K	–	422
2025 Q4	$1.04K	Buy	+15	New	+$612	﹤0.01%	484

Other funds holding GPCR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Bellevue Asset Management's GPCR Position: Q1 2026 in Review

Bellevue Asset Management sold out of Structure Therapeutics (GPCR) in Q1 2026, closing a stake of 15 shares — an estimated $1.04K sold.

Bellevue Asset Management first reported a position in GPCR in Q4 2025 and held it in 1 quarter. The position peaked at $1.04K in Q4 2025. 196 funds tracked by Wall St. Rank hold GPCR as of Q1 2026.

Bellevue Asset Management reported no remaining Structure Therapeutics position as of Q1 2026 after selling out during the quarter.
Bellevue Asset Management sold 15 Structure Therapeutics shares in Q1 2026, an estimated $1.04K.
Bellevue Asset Management first reported a position in Structure Therapeutics in Q4 2025 and held it in 1 quarter.
Bellevue Asset Management's Structure Therapeutics position peaked at $1.04K in Q4 2025.
196 funds tracked by Wall St. Rank held Structure Therapeutics as of Q1 2026.

Based on Bellevue Asset Management's 13F filing for Q1 2026, filed 24 Apr 2026.